483
Wockhardt USA LLCWockhardt USA LLC – FDA 483, Jun 6, 2024
Record Details
An FDA inspection of Wockhardt USA LLC identified significant deficiencies in post-marketing surveillance and reporting. The firm lacked written procedures for monitoring adverse drug experiences and failed to submit numerous required periodic adverse drug experience reports and annual reports for its ANDA products. These issues indicate a systemic problem with regulatory compliance regarding drug safety and reporting obligations.
- Person
View Company Profile
ID · 646e029d-7dc3-46c4-8ff5-d58aad18c420
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.